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Abstract 
To clarify the hemodynamic changes under balloon occlusion of the hepatic artery and to identify predictors of the 
short-term therapeutic effect (TE) after balloon-occluded transcatheter arterial chemoembolization using miriplatin 
(B-TACE) for hepatocellular carcinoma (HCC). Tumor variables and angiographic data were collected for 35 nodules (29 
patients) with a B-TACE for HCC. Lesions were classified into three groups based on the balloon-occluded CT hepatic 
arteriography (BO-CTHA) results: Group A, presence of corona enhancement; Group B, absence of corona enhance-
ment; Group C, decreased perfusion or perfusion defect compared to standard CTHA. Objective response was 
defined as TE3/4, and poor TE as TE1/2, evaluated by response evaluation criteria in cancer of the liver at 1–4 months 
after the procedure. Univariate analysis revealed that proximal level of balloon occlusion, intratumoral lower CT values 
immediately after treatment and BO-CTHA findings were significantly correlated with poor TE (p = 0.034, 0.037, and 
0.003, respectively). Multivariate logistic analysis identified the Group C as a significant factor associated with the 
worse short term TE (odds ratio 8.34; 95 % confidence interval 1.49–68.8). Partial or complete perfusion defect on BO-
CTHA was an independent factor associated with poor therapeutic effect.
© 2016 Asayama et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Transcatheter arterial chemoembolization (TACE) is a 
widely accepted and effective therapy for unresectable 
hepatocellular carcinoma (HCC; Llovet et al. 2002). Vari-
ous anticancer drugs can be used for TACE, including 
doxorubicin, epirubicin, cisplatin and mitomycin, but the 
superiority of any particular drug in terms of effective-
ness has not been established (Ishikawa et al. 2014). Miri-
platin hydrate (Miripla®; Dainippon Sumitomo Pharma 
Co., Osaka, Japan), which has the same diaminocyclohex-
ane structure as oxaliplatin, is a lipophilic derivative 
that can be suspended in lipiodol (Hanada et  al. 2009), 
became commercially available in 2010. Theoretically, 
miriplatin is a good agent in terms of its higher solubility, 
stability in lipiodol, and gradual release within the tumor. 
However, a 2012 study revealed that the rate of local 
recurrence in patients treated with miriplatin was sig-
nificantly higher than that in patients treated with epiru-
bicin with mitomycin (Miyayama et al. 2012). This is due 
to the high viscosity of miriplatin–lipiodol suspension 
(Kora et al. 2013). Some researchers have tested creative 
TACE methods to overcome the high viscosity problem 
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and improve the therapeutic effect (TE); these methods 
including warming miriplatin (Kora et al. 2013) and bal-
loon-occluded TACE (B-TACE; Ishikawa et al. 2014).
B-TACE was first introduced by Irie et al. (2013). They 
reported that selective B-TACE with doxorubicin and 
mitomycin induced dense lipiodol accumulation in HCC 
nodules. Ishikawa et al. (2014) revealed that B-TACE with 
miriplatin achieved relatively good local control of HCC 
(local recurrence rate, 11.1 % at 6 months and 26.2 % at 
12 months). The mechanism of this improved local con-
trol effect might be explained by the presence of anasto-
motic vessels, the viscosity of lipiodol emulsion, and the 
difference in size between the peripheral vessels in nor-
mal parenchyma and the vessels feeding into the HCC 
(Irie et  al. 2013). Ishikawa et  al. (2014) mentioned that 
altering hemodynamics might be a main factor under 
balloon occlusion.
Computed tomography during hepatic arteriography 
(CTHA) is a sophisticated method for estimating the 
hepatic arterial flow. We speculated that CTHA under 
balloon occlusion can provide useful information for the 
analysis of hemodynamic changes. The aim of the present 
study was to reveal the relationship between changes of 
arterial flow in HCC nodules under balloon occlusion 
and local TE by means of CTHA. We also addressed 




This retrospective clinical study was approved by the 
ethics committee of our hospital. The requirement for 
informed patient consent was waived. From May 2014 
to August 2014, 50 consecutive patients with hypervas-
cular HCC who were scheduled to receive B-TACE using 
miriplatin were evaluated. The exclusion criteria were: 
(1) death after B-TACE (pneumonia, one case; rupture of 
duodenal varices, one case); (2) HCCs with a total sum of 
tumor dias. > 6 cm according to a previous report (Kora 
et al. 2013; seven cases), additional treatment such as sur-
gical resection, radiofrequency ablation or percutaneous 
ethanol injection therapy before the follow up CT (seven 
cases), or chemotherapy without embolization (five 
cases).
Finally, a total of 29 patients with 35 HCC nodules 
were enrolled in this study. The clinical characteristics 
of the study population are summarized in Table 1. All 
patients underwent pretreatment physical and labora-
tory examinations, ultrasound, and three-phase dynamic 
CT or gadoxetic-enhanced MRI. Hypervascular HCC 
was diagnosed by means of the imaging findings in 
addition to high serum levels of tumor markers [alpha-
fetoprotein (AFP) and d-gamma-carboxyprothrombin 
(DCP)]. The mean tumor diameter was 16.6 mm (range 
9–40 mm).
TACE
For each patient, the TACE procedure was as follows. 
The femoral artery was catheterized under local anes-
thesia, and a 4-Fr catheter was inserted into the celiac 
or common hepatic artery. Then a 1.8-Fr coaxial micro-
balloon catheter (Logos, Piolax, Yokohama, Japan) was 
advanced into the hepatic artery that supplied the entire 
target tumor. CT hepatic arteriography was performed 
before and after inflation of the balloon. Subsequently, 
miriplatin–lipiodol suspension was injected followed 
by gelatin sponge particle (Gelpart; Nippon Kayaku, 
Tokyo). Miriplatin was prepared by mixing 30 or 60 mg 
(1 or 2 vials) of miriplatin hydrate in 3 or 6 mL of lipi-
odol. The maximum dose of miriplatin was limited to 
120 mg.
CTHA
CTHA was performed with an interventional radiology 
computed tomography (IVR-CT) system (Infinix Celeve/
Active, Toshiba Medical Systems, Tokyo). This system 
is equipped with 16 detector-row CT. The catheter tip 
was advanced as close to the tumor as possible. Standard 
CTHA and CTHA with balloon occlusion (BO-CTHA) 
were performed for the area(s) containing at least one 
HCC nodule.
The parameters for the scanning were as follows: colli-
mation, 1 mm; reconstruction, 3 mm; pitch, 15: amperage, 
300 mA s; kilovoltage, 120 kVp. The CTHA data acquisi-
tion began 7–10  s (first phase) and 30  s (second phase) 
after the initiation of a transcatheter hepatic arterial injec-
tion of 10–50 mL of nonionic contrast material (iopamidol, 
Table 1 Demographic characteristics and  pretreatment 
assessment of 29 patients who underwent B-TACE
Data are median and range in age, albumin, total bilirubin, prothrombin activity, 
platelet, AFP and DCP
HBV hepatitis B virus, HCV hepatitis C virus, AL alcohol, AFP alpha-fetoprotein, 
DCP des-gamma-carboxyprothrombin
Number of nodules, 1/2/3 24/4/1
Age, years 72 (39–83)
Gender, male/female 21/8
Etiology, HBV/HCV/AL/others 5/17/3/4
Child–Pugh class, A/B/C 25/4/0
Albumin, g/dL 3.6 (2.2–4.2)
Total bilirubin, mg/dL 1.0 (0.5–3.29)
Prothrombin activity, % 78 (51–111)
Platelets, ×103/µL 112 (31–219)
AFP, ng/mL 13.7 (2–3791)
DCP, AU/L 39 (9–2043)
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Iopamiron® 150 iodine, 150 mg I/mL; Bayer HealthCare, 
Osaka, Japan) at a speed of 0.5–2.5 mL/s using the auto-
mated power injector. The appropriate injection rate for 
CTHA was determined to be the maximum injection 
rate (which basically depended on the vessel caliber) that 
would not cause a backward flow of contrast material on 
the hepatic arteriography. The injection rate was the same 
before and after the inflation of the balloon. The contrast 
medium was injected until the completion of the scanning 
of the first phase. Plain CT was performed immediately 
after the B-TACE. When the plain CT showed the insuf-
ficient lipiodol accumulation in the target tumor, we per-
formed the additional TACE without balloon occlusion 
from another artery in the same session.
Assessment of the CT findings
Two experienced abdominal and interventional radi-
ologists (AN, YU) blinded to the patients’ information 
retrospectively reviewed the findings obtained by the 
standard CTHA and BO-CTHA and the post-treatment 
plain CT. The tumor locations were classified into two 
groups: the central portion of the liver (segments 1 and 
4) and others (segments 2, 3 and 5–8). All lesions were 
classified into one of the following groups on the basis 
of the enhancement pattern observed on CTHA: Group 
A, nodules that showed high enhancement accompa-
nied by corona enhancement (Ueda et  al. 1998) on the 
BO-CTHA (Fig.  1a–d); Group B, nodules that showed 
high enhancement without corona enhancement on the 
BO-CTHA (Fig.  1e, f ); Group C, nodules that showed 
decreased enhancement or perfusion defect on BO-
CTHA compared to standard CTHA, regardless of 
corona enhancement (Fig. 2). Corona enhancement was 
defined as peritumoral contrast enhancement on the 
second phase of CTHA (Ueda et al. 1998). The CT value 
of lipiodol in the HCC nodule was measured by using a 
region of interest (ROI) in the tumor. The lesion density 
is presented in Hounsfield units (HUs) on CT.
Fig. 1 A 73-year-old male with two HCCs (thick arrow, arrowhead) in segment 4. a Digital subtraction angiography (DSA) showed two hypervascular 
masses (cranial: thick arrow, caudal; arrowhead). Note the deflated balloon at the tip of catheter (thin arrow). b Second phase BO-CTHA in segment 
4 showed corona enhancement around the tumor. This tumor was classified as Group A. c Plain CT obtained immediately after B-TACE showed 
good accumulation in the tumor, but a CT value measured relatively low at 788 HU, and contrast-enhanced CT at 2 months after B-TACE d showed 
the washout of lipiodol and early enhancement in the tumor (thin arrow), indicating poor TE. e Second-phase BO-CTHA in segment 4 did not show 
corona enhancement around the tumor. This tumor was classified as Group B. Plain CT obtained immediately after B-TACE showed good accumula-
tion in the tumor with a high CT value at 1408 HU (not shown). f Contrast-enhanced CT at 2 months after B-TACE showed dense lipiodol accumula-
tion in the tumor. The tumor decreased in size without early enhancement
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Assessment of the therapeutic effect (TE)
The assessment of chemoembolization was evaluated by 
dynamic CT at 1–4  months after B-TACE. The degree 
of lipiodol accumulation was classified into four grades 
according to the response evaluation criteria in cancer 
of the liver (Kudo et al. 2010). The four TE grades were 
defined as follows: TE4, 100  % necrosis/size of tumor; 
TE3, 50–99  %; TE2, up to 50  % or tumor enlargement 
<  25  %; and TE1, tumor enlargement of 25  % or more, 
regardless of the extent of necrosis (Kudo et al. 2010). TE 
is classified into two groups: objective response (good 
TE), TE3 and TE4; poor TE, TE2 and TE1.
Statistical analysis
We examined the categorical variables by Fisher exact 
test. These variables included sex (male, female), 
Child–Pugh class (A, B, C), AFP (<20, ≥20), DCP (<40, 
≥40), previous TACE (yes, no), location of tumor (seg-
ment 1/4, others), and level of balloon occlusion (periph-
eral to the subsegmental branch, segmental to lobar 
branch). We used the Kruskal–Wallis test to analyze 
the association between the CTHA findings (Group 
A, B, C) and the TE; first, we compared the TE among 
three groups. If a significant difference was obtained, we 
compared it between each pair of groups using the Chi-
square test. Continuous variables such as age and CT 
value were examined by Student t test. All variables found 
to be significant in a univariate analysis were entered into 
the multivariate logistic regression analysis. All statisti-
cal analyses were performed with JMP software (version 
11, SAS Institute) for Microsoft Windows. Differences at 
p < 0.05 were considered to be significant.
Fig. 2 An 67-year-old male with HCC in segment 2. a Arterial phase of dynamic CT showed a hypervacular mass (arrow). b DSA in segment 2 
showed a tumor stain (arrow). c First-phase standard CTHA in segment 2 showed a round hypervascular mass (arrow). d First-phase BO-CTHA in 
segment 2 showed a perfusion defect (arrowhead) in the tumor. e Plain CT obtained immediately after B-TACE showed good accumulation in the 
tumor with a CT value of 833 HU. f Arterial phases of dynamic CT at 3 month after B-TACE showed lipiodol washout and early enhancement, indi-
cating a poor TE. Despite the relatively high CT value immediately after B-TACE, most of the lipiodol was washed out. This is presumably because the 
inflow from the peribiliary plexus or isolated artery would wash away the lipiodol suspension
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Results
The number of TE4, TE3, TE2, and TE1 were 3, 17, 6 and 
9, respectively. The results are shown in Table 2. Objec-
tive response rate was 42.9  % (15 of the 35 lesions) at 
1–4 months after B-TACE. There was no significant dif-
ference between the poor (TE1/2) and good (TE3/4) 
groups in age, sex, Child–Pugh class, AFP level, DCP 
level, history of previous TACE or tumor location. Thir-
teen of the 23 tumors who were injected with miriplatin–
lipiodol suspension from a peripheral to subsegmental 
branch showed a good response (TE3/4), whereas 2 of 
the 12 tumors who were injected with miriplatin–lipiodol 
suspension from a segmental branch to lobar branch 
showed a poor response (TE1/2), a significant difference 
(p = 0.034). The CTHA findings and TE were significantly 
correlated (p  =  0.003). The Group C tumors (Fig.  2) 
showed significantly poor TE compared to the Group B 
tumor (Fig. 1e, f ) (p = 0.002). Groups A (Fig. 1a–d) and 
C differed but not significantly (p  =  0.075). There was 
no significant difference between Group A and Group 
B (p  =  0.350). CT obtained immediately after B-TACE 
showed the lipiodol accumulation in the entire lesions of 
the all cases regardless of CTHA findings. The CT val-
ues of the lesions ranged from 246 to 1407 (mean; 781) 
and were correlated with the TE (p = 0.037). As shown 
in Table 3, multivariate logistic regression analysis identi-
fied the Group C as a significant factor associated with 
the worse short term TE bearing an odds ratio of 8.34 
(95 % confidence interval 1.49–68.8).
Discussion
The therapeutic efficacy of TACE using miriplatin has 
been controversial. Otsuji et al. (2015) reported that cis-
platin and miriplatin had equal efficacy for TACE and 
transcatheter arterial infusion (TAI) in a randomized 
controlled trial. Oguro et al. (2012) reported that TACE 
using a miriplatin–lipiodol suspension yielded worse 
short term responses than cisplatin–lipiodol suspension. 
Handa et al. (2014) reported that miriplatin was superior 
to epirubicin in the short term but inferior in the long 
term, whereas Miyayama et al. (2012) observed that the 
local recurrence in patients who were treated with miri-
platin was significantly higher than those treated with 
epirubicin plus mitomycin C, because the high viscos-
ity of miriplatin causes an inadequate distribution in the 
tumor and early washout.
Ishikawa et  al. (2014) mentioned that B-TACE is a 
promising method for improving treatment with miripl-
atin. B-TACE, originally developed by Irie et al., achieved 
good accumulation of lipiodol emulsion in the HCC nod-
ules. They reported that in the setting of a balloon occlu-
sion, lipiodol emulsion ceased to flow in the peripheral 
vessels supplying liver parenchyma but still continued to 
flow into HCC nodules in the majority of the cases (Irie 
et  al. 2013). In some cases, lipiodol emulsion did not 
Table 2 Therapeutic effect after  balloon-occluded tran-
scatheter arterial chemoembolization using miriplatin 
for hepatocellular carcinoma
AFP alpha-fetoprotein, DCP des-gamma-carboxyprothrombin
Therapeutic effect p value
Poor (TE1/2) Good (TE3/4)
Age
 Mean ± SD 73.1 ± 2.1 70.1 ± 2.5 0.366
Sex
 Male 16 11 0.700
 Female 4 4
Child–Pugh class
 A 17 11 0.430
 B 3 4
 C 0 0
AFP (ng/mL)
 <20 12 10 0.928
 ≥20 8 5
DCP (mAU/mL)
 <40 8 9 0.315
 ≥40 12 6
History of previous TACE
 Yes 13 11 0.721
 No 7 4
Tumor location
 S1 or S4 6 2 0.419
 Others 14 13
Level of balloon occlusion:
 Peripheral/subsegmental 10 13 0.034
 Segmental/lobar 10 2
CTHA finding
 Group A 5 5 0.003
 Group B 2 8
 Group C 13 2
CT value after B-TACE (HU) 711.8 ± 74.2 958.5 ± 85.7 0.037
Table 3 Multivariate logistic analysis for  the short term 
poor therapeutic effect (good vs poor)
CI confidence interval, CTHA CT hepatic arteriography, B-TACE balloon-occluded 
transcatheter arterial chemoembolization, HU Hounsfield unit
Factors Odds ratio 95 % CI p value
Level of balloon occlusion 
(segmental/lobar)
3.59 0.53–33.0 0.191
CTHA finding (Group C) 8.34 1.49–68.8 0.015
CT value after B-TACE (HU) 0.38 0.007–15.0 0.608
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show stagnation in the peripheral vessels supplying the 
liver parenchyma, leading to poor local control (Irie et al. 
2013). Ishikawa et al. (2014) speculated that the mecha-
nism underlying the good accumulation of lipiodol is 
essentially an alteration of the hemodynamics under bal-
loon occlusion.
Three types of hepatic artery play an important role 
in the hemodynamic change under balloon occlusion 
(Irie et  al. 2013): peribiliary plexus (Cho and Lunder-
quist 1983), interlobar communicating arcade (Tohma 
et al. 2005), and isolated artery (Ekataksin 2000) (Fig. 3). 
In Group A, the corona phenomenon (Ueda et al. 1998) 
was observed in the second phase of BO-CTHA. We 
think that in this group, the arterial blood pressure did 
not decrease due to prominent collateral arterial flow 
such as that in the peribiliary plexus and interlobar com-
municating arcade beyond the occluded portion or due 
to inadequate balloon inflation. Thus, the intratumoral 
arterial blood pressure overcomes the portal venous 
pressure surrounding the tumor, resulting in the corona 
phenomenon.
The corona phenomenon was not observed in Group 
B, in which the intratumoral arterial pressure probably 
decreased and might be nearly equal to the portal venous 
pressure in the surrounding tumor. In such a condition, 
the corona phenomenon cannot be seen. In the present 
study, even though no significant difference was observed 
in local control between Groups A and B, there was a 
tendency for Group B to show better local control than 
Group A. Lipiodol suspension could be pushed into the 
tumor and into the area of corona enhancement more 
easily in Group B.
In Group C, we suspect that collateral tumor ves-
sels such as the isolated artery feed directly the tumor 
instead of the original feeding artery under the condi-
tion of balloon occlusion. In the beginning of the infu-
sion, most of the lipiodol suspension runs through 
the artery in the noncancerous liver parenchyma but 
instantly ceases to flow, and then it flows into the origi-
nal feeding artery, leading to a good accumulation of 
lipiodol suspension in the tumor immediately after 
treatment. However, because collateral tumor vessels 
may develop well in such tumors, the lipiodol would 
wash out rapidly.
In the present study, the TE was worse than that in a 
previous evaluation (Ishikawa et  al. 2014) showing an 
only 11 % overall local recurrence rate at 6 months. This 
might be due to the development of the collateral arterial 
Fig. 3 Changes in the intrahepatic arterial flow with and without balloon occlusion. Without balloon occlusion, the feeding artery flows into the 
tumor and drains out to the hepatic parenchyma, forming corona enhancement. In Group A, the feeding artery is reconstructed by the peribiliary 
plexus and communicating arcade distal to the balloon occlusion. The arterial inflow was kept in the tumor, and the intra-arterial pressure around 
the tumor was preserved. Corona enhancement was thus observed. In Group B, the collateral arteries such as the peribiliary plexus and commu-
nication arcade do not develop enough to maintain the intratumoral arterial pressure. Corona enhancement is not present in this group. In Group 
C, collateral arteries including the isolated artery, peribiliary artery and communicating arcade feed the tumor entirely or partially. These flows do 
not contain contrast material, and thus CTHA shows decreased perfusion or perfusion defect. CA catheter, FA feeding artery, N the area of contrast 
distribution in noncancerous liver parenchyma, T tumor, C coronal enhancement, BA balloon (inflated), PP peribiliary plexus, CoA communicating 
arcade, IA isolated artery
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flow during the BO-CTHA. Taking time to perform BO-
CTHA could allow the development of the collateral 
arterial flow into the tumor even for just a short while, 
causing early washout of lipiodol after treatment.
There were no significant differences between the good 
TE group and the poor TE group in age, sex, Child–
Pugh class, previous TACE, or tumor location. As for 
tumor location, even though no significant difference 
was observed, 6 of 8 tumors (75  %) in the central por-
tion (segments 4 and 1) showed a poor therapeutic effect. 
This is probably because the catheter access for the feed-
ing artery is difficult in segments 4 and 1 in general, and 
migration or spillover of the drug into the communicat-
ing arcade is frequent.
With regard to the occlusion level of balloon, our prox-
imal occlusion cases (segmental or lobar artery) showed 
poor TE. This may be because a large amount of drug 
was delivered in the noncancerous liver parenchyma, 
thus the amount of drug into the tumor would be smaller 
compared to the cases treated with the infusion of drug 
from a peripheral to subsegmental artery and because 
the intratumoral arterial pressure would not decrease 
enough due to collateral flow. Finally, the plain CT value 
immediately after treatment was a predictive factor of TE 
in our study, which is in concordance with the previous 
report (Ishikawa et al. 2014).
The present study has several limitations. First, the 
CTHA was not performed for all of the lesions for each 
case. In the cases of multiple lesions, the largest lesion 
was selected for CTHA, in principle. This could have 
caused lesion selection bias. Second, the patients who 
had undergone chemolipiodolization without emboliza-
tion using gelatin sponge particles were excluded from 
this study, and this could also have caused patient selec-
tion bias. Third, the viscosity is different between the 
contrast material and the lipiodol suspension. The distri-
bution pattern of contrast material would not correspond 
to that of the lipiodol suspension precisely. Furthermore, 
CTHA is a complicated method and involves large radia-
tion dose. However, we believe that it would be of benefit 
to understand the hemodynamic changes in the tumor 
under the balloon occlusion of the hepatic artery. Fourth, 
we did not evaluate overall survival or long term TE. We 
consider, however, that the short term TE may be directly 
related to prognosis of the patients. Fifth, the number of 
patients was relatively small.
In conclusion, the intratumoral arterial flow can 
change, presumably due to a collateral pathway under 
balloon occlusion. B-TACE for HCC lesions showing 
decreased perfusion or perfusion defect on BO-CTHA 
compared to standard CTHA can be expected to achieve 
only a poor short-term therapeutic effect as well as a 
proximal level of balloon occlusion and lower CT value 
immediately after treatment. In the multivariate logistic 
analysis, decreased perfusion or perfusion defect on BO-
CTHA was found to be an independent factor associated 
with poor therapeutic effect.
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